Related Experiment Video
Updated: Feb 25, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
Nele Van Der Steen1, Yves Mentens2, Marc Ramael3
1Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Department of Pathology, Antwerp University Hospital, Antwerp, Belgium; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Identifying targeted therapy for non-small cell lung cancer with multiple driver mutations is challenging. This case series reviews responses to targeted therapies in patients with double oncogenic driver mutations, including EGFR and ALK.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) treatment increasingly involves targeted therapies for specific oncogenic drivers.
- Advancements in genetic testing reveal more NSCLC cases with multiple driver mutations, posing treatment selection challenges.
Observation:
- This case series examines patient responses to targeted therapies for NSCLC with intrinsic double oncogenic driver mutations.
- Focus areas include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), cMET, and Kirsten rat sarcoma viral oncogene (KRAS).
- An unpublished case of a patient with concurrent EGFR L858R and cMET exon 14 skipping mutations is presented.
Findings:
- The study analyzes the efficacy of targeted therapies in NSCLC patients harboring dual oncogenic driver mutations.
- Specific attention is given to the effectiveness of treatments targeting EGFR, ALK, cMET, and KRAS pathways.
Implications:
- Findings may aid clinicians in selecting appropriate targeted therapies for NSCLC patients with complex mutational profiles.
- Understanding treatment responses in double-mutation NSCLC can guide future therapeutic strategies and drug development.
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Gene Conversion
Abnormal Proliferation

